ART-hero-image-1920
Common_Pitfalls_in_Cell_Therapy_Studies_Title_Card_d01

 

Common Pitfalls in Cell Therapy Studies

 

Listen as Kevin Hennegan, Senior Regulatory Strategist for Veristat, shares some of the common hurdles drug developers face when bringing cell therapies to market including international regulatory variability, patient safety assurance, planning for long-term follow-up and more.

 

Play another episode from our library

 

ART_logo_reversed_horizontal_stacked


Listen and subscribe on your favorite podcast player

  apple-podcast-badge EN_Google_Podcasts_Badge_1x spotify-podcast-badge-blk-grn-330x80 

  • Privacy Policy

© 2025 Veristat, Inc. All Rights Reserved.

Return to Top